Are you looking for blue chip ASX 200 shares to add to your portfolio this financial year? If you are, the two ASX shares listed below could be worth a closer look.
Here’s what analysts think of these shares:
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to look at is CSL. It is one of the world’s leading biotherapeutics companies, comprising the CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies and Seqirus is the second largest influenza vaccines business.
Both of CSL’s businesses have been growing at a solid rate in recent years and have been tipped to continue doing so in the future. This is being driven by their leading therapies and lucrative research and development pipelines.
In respect to the latter, CSL’s pipeline contains a number of highly promising products that have the potential to generate significant revenues in the future.
And while plasma collection headwinds are likely to weigh on its performance in the near term, this is understood by the market and priced into the current CSL share price.
UBS is positive on the company. The broker currently has a buy rating and $330.00 price target on its shares.
REA Group Limited (ASX: REA)
Another blue chip ASX 200 share to consider is REA Group. This property listings company has been a strong performer in recent years despite battling a housing market downturn and the COVID-19 pandemic.
This demonstrates the resilience of REA Group’s business model and its exceptionally strong position in the ANZ market.
Positively, with the housing market now thriving once again, REA Group’s growth outlook is looking increasingly positive. This should be boosted by price increases, new revenue streams, acquisitions, and its cost control.
It is for this reason that the team at Goldman Sachs is particularly positive on the company. So much so, the broker has recently retained its buy rating and lifted its price target to a lofty $198.00.